Does a 3-week stall on GLP-1s really mean you're done losing weight?
Quick answer
GLP-1 receptor agonist therapy produces weight loss that typically plateaus between 12 and 18 months depending on the agent and dose, with tirzepatide showing more prolonged loss curves than semaglutide in head-to-head trial designs. Metabolic adaptation and lean mass loss are documented side effects of caloric restriction during GLP-1 use and warrant clinical monitoring, particularly protein intake and resistance exercise counseling. Discontinuation without medical guidance carries a clinically significant regain risk supported by withdrawal extension trial data, and decisions about stopping or tapering should involve the prescribing clinician.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @dietcoach4u actually say?
The creator claimed that a plateau lasting "30 or more weeks" with no weight or inch loss means you are "done losing weight on the medicines." They cited "FDA trial data" to argue that GLP-1 medications only produce weight loss for "nine to 14 months" on average. They also said that "every single jab you take, your metabolism falls," that a 30% decrease in thyroid function occurs, and that quitting leads to "60 to 70% weight regain within one year." The video ends with a pitch for their specialist practice to help patients "come off the medicines by fixing root causes."
The creator is mixing real pharmacology data with significant exaggerations and some claims that are not supported by published evidence. A few things they said land close to the truth. Several others do not.
Does the science back this up?
Partially. The claim that weight loss slows and eventually plateaus on GLP-1 therapy is well-documented. The 60-70% regain figure after stopping is also grounded in real trial data. The rest gets shakier fast.
The STEP 1 trial (Wilding et al., 2021, NEJM) showed that semaglutide 2.4mg produced most of its weight loss within the first 60-68 weeks, with a plateau forming around week 60. That is closer to 14-15 months, not a hard cutoff at 9 months. The SURMOUNT-1 trial for tirzepatide (Jastreboff et al., 2022, NEJM) showed weight loss continuing meaningfully past 12 months in many participants, with the curve still declining at week 72. So the "done at 9-14 months" framing is a rough approximation at best and actively misleading for tirzepatide users.
The regain data comes from the STEP 1 withdrawal extension (Wilding et al., 2022, Diabetes, Obesity and Metabolism), which found participants regained about two-thirds of lost weight within 12 months of stopping. That part checks out.
What did they get wrong (or right)?
The metabolic adaptation claim is real but badly overstated. Adaptive thermogenesis, the reduction in resting metabolic rate beyond what weight loss alone predicts, does occur. Müller and Bosy-Westphal (2013, Obesity Reviews) confirmed this in caloric restriction contexts. But the creator's claim that "every single jab you take, your metabolism falls" implies a linear, drug-driven metabolic crash. That is not what the literature shows. GLP-1 agonists reduce food intake; the metabolic slowdown follows the weight loss, not the injection itself.
The "30% decrease in thyroid function" claim is the most problematic statement in the video. There is no published clinical trial data supporting a 30% reduction in thyroid function as a standard outcome on GLP-1 therapy. GLP-1 receptors exist in thyroid tissue, which is why rodent studies prompted the boxed warning about thyroid C-cell tumors for semaglutide and liraglutide. But thyroid function suppression at 30% in humans is not an established finding. This claim is unverifiable at best and fear-mongering at worst.
The muscle loss concern is legitimate. Cava et al. (2017, Nutrients) and more recent analyses of GLP-1 trial data do show lean mass loss during rapid weight reduction, which is a real clinical concern worth discussing with a prescribing provider.
What should you actually know?
Plateaus on GLP-1 medications are normal and expected. They do not automatically mean the drug has stopped working or that you need to "fix hormones and metabolism" with a specialist's paid program. A plateau often reflects the drug doing exactly what it is supposed to do: reducing appetite until intake matches a new, lower equilibrium weight.
If you have been on a stable GLP-1 dose for many months with no weight change, the most evidence-supported next steps include dose optimization with your prescribing clinician, resistance training to preserve lean mass, and a reassessment of dietary protein intake. None of those require leaving your current care team.
Stopping GLP-1 therapy without medical supervision based on a social media timeline is not recommended. The regain risk is real. Any decision to taper or discontinue should happen with a licensed provider who knows your full medical history, not based on a 3-week stall benchmark from a TikTok video.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Does a 3-week stall on GLP-1s really mean you're done losing weight?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Does a 3-week stall on GLP-1s really mean you're done losing weight? is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
GLP-1 receptor agonist therapy produces weight loss that typically plateaus between 12 and 18 months depending on the agent and dose, with tirzepatide showing more prolonged loss curves than semaglutide in head-to-head trial designs.
FormBlends verdict
GLP-1 receptor agonist therapy produces weight loss that typically plateaus between 12 and 18 months depending on the agent and dose, with tirzepatide showing more prolonged loss curves than semaglutide in head-to-head trial designs. Metabolic adaptation and lean mass loss are documented side effects of caloric restriction during GLP-1 use and warrant clinical monitoring, particularly protein intake and resistance exercise counseling. Discontinuation without medical guidance carries a clinically significant regain risk supported by withdrawal extension trial data, and decisions about stopping or tapering should involve the prescribing clinician.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonist therapy produces weight loss that typically plateaus between 12 and 18 months depending on the agent and dose, with tirzepatide showing more prolonged loss curves than semaglutide in head-to-head trial designs. Metabolic adaptation and lean mass loss are documented side effects of caloric restriction during GLP-1 use and warrant clinical monitoring, particularly protein intake and resistance exercise counseling. Discontinuation without medical guidance carries a clinically significant regain risk supported by withdrawal extension trial data, and decisions about stopping or tapering should involve the prescribing clinician.
- STEP 1 trial data (Wilding et al., 2021, NEJM) shows semaglutide weight loss plateau forming around week 60, roughly 14-15 months, not a flat 9-month cutoff.
- Tirzepatide in SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed continued weight loss past 72 weeks in many participants, making a universal 9-14 month endpoint inaccurate for all GLP-1 agents.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- STEP 1 trial data (Wilding et al., 2021, NEJM) shows semaglutide weight loss plateau forming around week 60, roughly 14-15 months, not a flat 9-month cutoff.
- Tirzepatide in SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed continued weight loss past 72 weeks in many participants, making a universal 9-14 month endpoint inaccurate for all GLP-1 agents.
- The 60-70% regain figure after stopping is supported by real trial data (Wilding et al., 2022, Diabetes, Obesity and Metabolism) and is a legitimate reason not to discontinue without medical guidance.
- Metabolic adaptation during GLP-1 use is real but follows caloric restriction and weight loss, not the injection itself; the framing that each dose crashes metabolism is not supported by the literature.
- The claim of a '30% decrease in thyroid function' has no published clinical trial support in humans and should not be used to alarm patients or justify unmonitored medication changes.
- Lean mass loss during rapid weight reduction on GLP-1 therapy is a documented concern; resistance training and adequate protein intake are evidence-supported countermeasures worth discussing with your provider.
- A 3-week stall does not meet any clinical threshold for GLP-1 treatment failure; decisions about dose changes or discontinuation should involve a licensed prescribing clinician, not a social media timeline.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dustin Holston the Biohacker · TikTok creator
1.0K views on this video
How do you know that you are done with weight loss on glp? Once you stall for 3 or more weeks, of no weight loss or inches, chances are you are done with weight loss unless you fix hormones and metabolism. Let’s get you losing next week! #diet #weightloss #stall
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dustin Holston the Biohacker, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.